Buy Mankind Pharma, target price Rs 2650: Motilal Oswal
Reuters
Synopsis
Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 89132.93 Crore) operating in Pharmaceuticals sector.
By ETMarkets.com
Motilal Oswal has buy call on Mankind Pharma with a target price of Rs 2650. The current market price of Mankind Pharma is Rs 2211.5.
Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Royalty Income for the year ending 31-Mar-2023.
Financials
For the quarter ended 31-03-2024, the company reported a Consolidated Total Income of Rs 2533.23 Crore, down -5.37 % from last quarter Total Income of Rs 2677.09 Crore and up 20.62 % from last year same quarter Total Income of Rs 2100.18 Crore. Company reported net profit after tax of Rs 474.18 Crore in latest quarter.
Promoters held 74.88 per cent stake in the company as of 31-Mar-2024, while FIIs owned 9.87 per cent, DIIs 11.14 per cent.
(You can now subscribe to our ETMarkets WhatsApp channel)
ADVERTISEMENT
Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 89132.93 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Royalty Income for the year ending 31-Mar-2023.
Financials
For the quarter ended 31-03-2024, the company reported a Consolidated Total Income of Rs 2533.23 Crore, down -5.37 % from last quarter Total Income of Rs 2677.09 Crore and up 20.62 % from last year same quarter Total Income of Rs 2100.18 Crore. Company reported net profit after tax of Rs 474.18 Crore in latest quarter.
ADVERTISEMENT
Promoter/FII Holdings Promoters held 74.88 per cent stake in the company as of 31-Mar-2024, while FIIs owned 9.87 per cent, DIIs 11.14 per cent.
(You can now subscribe to our ETMarkets WhatsApp channel)
Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
